Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Monopar TherapeuticsMNPR · Entity 5152 | Director | December 02, 2025 | December 08, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Monopar Therapeutics
Report date December 02, 2025 · Filed December 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $75.94 · Expires 2035-12-02 | Direct | 2,924 |
Reported balance
After 2025-12-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-02 · Grant · Acquired 2,924 · Balance 2,924 F1: Options vest 25% quarterly on March 31, 2026, June 30, 2026, September 30, 2026 and December 31, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Options vest 25% quarterly on March 31, 2026, June 30, 2026, September 30, 2026 and December 31, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 02, 2025 Filed Dec 8, 2025 16:48 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 2,924 | $0.00 Strike: $75.94 | $0.00 |
DisclosureSEC source: 0001437749-25-037167 · rdgdoc.xml · derivative · entry 1 Talukdar Lavina · CIK 0002059193 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,924 Underlying: Common Stock · 2,924 shares Expires 2035-12-02 F1 · derivative.exercise_date: Options vest 25% quarterly on March 31, 2026, June 30, 2026, September 30, 2026 and December 31, 2026. Read SEC document |
| March 04, 2025 Filed Mar 7, 2025 19:51 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 5,683 | $0.00 Strike: $31.70 | $0.00 |
DisclosureSEC source: 0001437749-25-006724 · rdgdoc.xml · derivative · entry 1 Talukdar Lavina · CIK 0002059193 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,683 Underlying: Common Stock · 5,683 shares Expires 2035-03-04 F1 · derivative.exercise_date: Options vest 25% quarterly on March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.